Analysis of combination anti-angiogenesis therapy on markers of coagulation, platelet activation and angiogenesis in patients with advanced cancer

被引：7
作者：
Caine, GJ
Harris, AL
Christodoulos, K
Lip, GYH
Blann, AD [1 ]
机构：
[1] Univ Dept Med, City Hosp, Haemostasis Thrombosis & Vasc Biol Unit, Birmingham B18 7QH, W Midlands, England
[2] Churchill Hosp, Canc Res UK, Med Oncol Unit, Oxford OX3 7LJ, England
来源：
CANCER LETTERS | 2005年 / 219卷 / 02期
关键词：
angiogenesis; platelets; soluble P-selectin; tissue factor; VEGF;
D O I：
10.1016/j.canlet.2004.09.036
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The effects of combination anti-angiogenesis therapy (marimastat, captopril and fragmin) on plasma levels of coagulation initiator tissue factor (TF), platelet marker soluble P-selectin and angiogenic vascular endothelial growth factor (VEGF) were tested in 25 patients with advanced cancer. They had higher soluble P-selectin (P < 0.001) and TF (P < 0.001), but not VEGF (P = 0.066) than 25 age and sex-matched controls. VEGF and TF correlated significantly (r = 0.8, P < 0.001) in cancer patients. Soluble P-selectin, TF and VEGF did not change at 4- and 8-weeks whilst on treatment. We provide further evidence linking coagulation and angiogenesis but combination anti-angiogenesis therapy does not influence plasma soluble P-selectin,TF or VEGF. (c) 2004 Published by Elsevier Ireland Ltd.
引用
收藏
页码：163 / 167
页数：5
相关论文
共 32 条
  • [1] Tissue factor expression and angiogenesis in human prostate carcinoma
    Abdulkadir, SA
    Carvalhal, GF
    Kaleem, Z
    Kisiel, W
    Humphrey, PA
    Catalona, WJ
    Milbrandt, J
    [J]. HUMAN PATHOLOGY, 2000, 31 (04) : 443 - 447
  • [2] Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor
    Abe, K
    Shoji, M
    Chen, J
    Bierhaus, A
    Danave, I
    Micko, C
    Casper, K
    Dillehay, DL
    Nawroth, PP
    Rickles, FR
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (15) : 8663 - 8668
  • [3] Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes
    Aguayo, A
    Kantarjian, HM
    Estey, EH
    Giles, FJ
    Verstovsek, S
    Manshouri, T
    Gidel, C
    O'Brien, S
    Keating, MJ
    Albitar, M
    [J]. CANCER, 2002, 95 (09) : 1923 - 1930
  • [4] Altomare D F, 2003, Tumori, V89, P5
  • [5] Belgore FM, 2001, AM J HEMATOL, V66, P59, DOI 10.1002/1096-8652(200101)66:1<59::AID-AJH1011>3.0.CO
  • [6] 2-Z
  • [7] Increased soluble P-selectin in patients with haematological and breast cancer: a comparison with fibrinogen, plasminogen activator inhibitor and von Willebrand factor
    Blann, AD
    Gurney, D
    Wadley, M
    Bareford, D
    Stonelake, P
    Lip, GYH
    [J]. BLOOD COAGULATION & FIBRINOLYSIS, 2001, 12 (01) : 43 - 50
  • [8] Plasma angiopoietin-1, angiopoietin-2 and Tie-2 in breast and prostate cancer: a comparison with VEGF and Flt-1
    Caine, GJ
    Blann, AD
    Stonelake, PS
    Ryan, P
    Lip, GYH
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2003, 33 (10) : 883 - 890
  • [9] In situ detection of tissue factor in vascular endothelial cells: Correlation with the malignant phenotype of human breast disease
    Contrino, J
    Hair, G
    Kreutzer, DL
    Rickles, FR
    [J]. NATURE MEDICINE, 1996, 2 (02) : 209 - 215
  • [10] DVORAK HF, 1995, AM J PATHOL, V146, P1029
1234